UDP-glucuronosyllransferases (UGTs) play an important role in detoxification of endo-and xenobiotics. Deficiencies of these enzymes can have serious consequences, for example, in CriglerNajjar disease Type I. Recently it was shown that the activated form of the abundant food-derived carcinogen 2-amino-l-methyl-6-phenylimidazo[4,5-Z)]pyridine (PhIP) is glucuronidated mainly by UGT1 isoforms. Therefore UGT1 deficiency may have an important impact on metabolism and excretion of PhIP in the body and consequently for the susceptibility toward carcinogenic effects through PhIP. To test this hypothesis we investigated fate and distribution of PhIP in the UGT1-deficient Gunn rat. In 2 h after intravenous injection of PhIP, Gunn rats excreted significantly more PhIP and metabolites than control animals, which were age-and weight-matched Wistar rats. In bile, both glucuronides of 7V-OH-PhIP were reduced but, in urine, only the ./V 3 -glucuronide was reduced while the A/ 2 -glucuronide was elevated. The metabolic pathway ratio between 4'-hydroxylation and Nhydroxylation was dramatically changed in the Gunn rat (five times higher in bile and doubled in urine, resulting in a four times higher ratio in total), mostly because of the doubled amount of 4'-PhIP-sulfate in Gunn rats compared to Wistar rats. Tissue levels of PhIP and metabolites were significantly lower in liver and colon of the Gunn rats. We conclude that, in Gunn rats, PhIP is alternatively metabolized through UGT2B enzymes and sulfotransferases, which adds another clue to the potential importance of sulfotransferases in detoxification of PhIP. e 2001 Academi c Press Key Words: PhIP; UDP-glucuronosyltransferases; sulfotransferases; Gunn rat; metabolism.
Glucuronidation is a crucial detoxification step in metabolism of xenobiotics. Two families of UDP-glucuronosyltrans- 1 To whom correspondence should be addressed. Fax: +31-20-5669190. E-mail, r.p.oude-elferink@amc.uva.nl.
ferases (UGTs)
2 catalyze the necessary reactions in glucuronidation of endogenous and exogenous compounds. The UGT1 gene, encoding nine isoforms, is localized on chromosome 2. The UGT2B genes, encoding unique proteins, represent the second UGT family (Mackenzie et al., 1997) . Several studies have defined the specificities and affinities of several UGTs toward a broad range of compounds (de Wildt et ai, 1999; Radominska-Pandya et ai, 1999; Strassburg et ai, 2000; Grove et ai, 2000; Nowell et ai, 1999) .
Lack of UGT 1 isoforms can lead to higher toxicity of drugs, as was shown for acetaminophen in the Gunn rat (de Morais and Wells, 1988) , which is lacking all isoforms of the UGT1 family. In this respect, this animal model represents most forms of the human Crigler-Najjar disease Type I (Chowdhury et ai, 1993) . Patients with frequent Gilbert's syndrome, which occurs in 6% of the population, mostly exhibit a homozygous mutation in the promotor region of the UGT1A1 isoform, thereby reducing the expression of this isoform (Bosma et ai, 1995) . Lack of this single isoform might already lead to adverse effects in drug toxicity (Iyer et ai, 1998) . Clinical evidence supports this hypothesis for the anticancer drug irinotecan (Wasserman et ai, 1997) ; furthermore, pharmacokinetics of acetaminophen (de Morais et ai, 1992) , josamycin (Okolicsanyi et ai, 1985) , and tolbutamide (Carulli et ai, 1976) were shown to be altered in Gilbert's syndrome. In addition, it is known that a few patients with Gilbert's syndrome exhibit heterozygous moderate deleterious mutations in the common UGT1 region, resulting in a 75% decrease of the activity of all UGT1 isoforms (Aono et ai, 1995; Monaghan et ai, 1996) . In those patients the detoxification of additional compounds might be impaired (Owens et ai, 1996) .
Since glucuronidation in general is an important detoxification step for many xenobiotics and carcinogens, lack of several isoforms or enzymes of UGT can result in a higher level of activated toxic or mutagenic compounds in the body. Hu and Wells (1992) showed for benzo [a] pyrene reduced glucuronida-tion in the Gunn rat and, as a consequence, higher covalent carcinogen binding to the tissue. Similar data were obtained in vitro for benzo [e] pyrene (Vienneau et al, 1995) and 4-(methylnitrosamino)-l-(3-pyridyl)-l-butanone (Kim and Wells, 1996) . It was shown recently that the activated form of the food-derived carcinogen 2-amino-1 -methyl-6-phenylimidazo[4,5-i]pyridine (PhIP), A/-OH-PhIP, is glucuronidated mainly by isoforms A3, A8, A9, and A10 of the UGT1 family (Nowell et al, 1999) . PhIP is a heterocyclic amine (Felton et al, 1986 ) that is very abundant in several forms of prepared meat (Skog et al, 1998) . It was shown to cause colon and breast carcinomas in rats (Ito et al, 1991) . As UGT1 isoforms play an important role in detoxification of PhIP, one can expect effects in Gunn rats similar to those for benz [a] pyrene. However, jV-OH-PhlP also can be glucuronidated by enzymes other than UGT1 (Nowell et al, 1999) , but the extent of this alternative glucuronidation has not been investigated. In addition, other phase II enzymes also may be able to compensate for UGT1 deficiency and ensure sufficient detoxification. To investigate whether UGT1 deficiency impairs detoxification of PhIP, we studied the metabolism and excretion of this compound in the Gunn rat. This animal model is particularly suitable for a metabolic study with PhIP for another reason: the differential expressions of CYP1A1 and 2, the two cytochrome isoforms activating PhIP to TV-OH-PhlP (Crofts et al, 1998) , have been well defined in jaundiced Gunn rats (Kapitulnik and Gonzalez, 1993) .
METHODS
We injected intravenously 2 /xCi/200 g rat [ w C]PhIP (specific activity 10 mCi/mmol, obtained from Toronto Research Chemicals, Inc., North York, Ontario, Canada, >99% pure) in female Gunn rats (RHA/jj from our own breeding colony) after anesthesia (50 mg pentobarbital sodium (Nembutal)/kg ip) and cannulation of the jugular vein, the common bile duct, and the urine bladder. A continuous intravenous infusion of tauroursodeoxycholic acid (200 nmol/min/200 g rat) was started to maintain bile flow. Bile and urine samples were obtained over a period of 2 h after injection. Control animals, female Wistar rats obtained from Harlan-CPB (Zeist, The Netherlands), were treated equally. All rats used for experiments were age-and weight-matched (age 12-16 weeks, 200-250 g weight) and were housed equally before experiments (12-h light/dark cycle, food and water ad libitum). Metabolites in bile and urine samples were separated by HPLC, using a system with Gynkotech-Pumps (Germering, Germany) and an Inertsil 5 ODS 3 column (Chrompack, Bergen op Zoom, The Netherlands). The mobile phase consisted of methanol in 0.1% diethylamine, pH 6.0, and the gradient was adjusted from 10 to 70% in 40 min. After injection of 20 /xl of sample we detected radioactivity with an online scintillation analyzer (515TR, Packard, Meriden, CT) and recorded UV and fluorescence spectra of major metabolites using a UV array detector (Applied Biosystems 1000S, Cheshire, UK) from 240 to 370 nm and an Aminco Bowman luminescence spectrometer (Spectronic, Cambridge, UK) with a fixed emission-excitation wavelength difference of 55 nm according to Crofts et al. (1997) . For identification and confirmation of metabolites we used enzyme studies (with ß-glucuronidase (bovine as well as Escherichia coli) and sulfatase, according to Kaderlik et ai. 1994a) , relative retention times on HPLC (Buonarati et ai, 1992; Watkins et ai, 1991a; Malfatti et at, 1996) , and UV and fluorescence spectra (Kadlubar et ai, 1995; Kaderlik et ai, 1994a; Crofts et ai, 1997) .
Additionally, we used previously obtained tandem mass spectrometry data (Quattro 2 triple quadruple mass spectrometer, Micromass, Manchester, UK) from bile and urine samples from Wistar and TR~ rats (C. G. Dietrich et ai, submitted for publication), where we identified all major metabolites of PhIP. The conditions for obtaining these data were as follows: The spectrometer was equipped with an electrospray source, source temperature 80°C, and nitrogen was used as spraying and drying gas. HPLC 30-s fractions, dried under nitrogen, were reconstituted in methanol/water ( 1:1 ) and were injected directly. The capillary voltage was 3500 and 3000 V for positive and negative ion scans, respectively. Both the cone voltage and the collision energy (for daughter-ion scans) varied for each fraction (cone voltage, approximately 35 V; collision energy, approximately 25 eV). Argon was used as collision gas at a pressure of 2.5 /nbar. With these conditions, the /v" 3 -glucuronide of N-OH-PhIP was identified with positive and negative ionization (mass 417 and 415, respectively), 4'-PhIP-sulfate was identified with negative ionization (mass 319) and 4'-OH-PhIP and PhIP itself were identified with positive ionization (mass 241 and 225, respectively). The yield of all other metabolites was too low to obtain mass spectrometry results, but these metabolites could be identified by relative retention times, enzyme treatment, and UV and fluorescence spectra (see above).
The retention time of a /V-OH-PhIP standard was determined after synthesis from nitro-PhIP as reported earlier by Lin et ai (1992) . For detection of A-OH-PhIP or its acetylated or sulfated form in blood, we used the method of Kaderlik et al. (1994a) .
After the last bile and urine samples in each experiment were taken, animals were killed through exsanguination from the aorta. Liver, whole intestine (with feces), kidney, pancreas, heart, and lungs were collected. We dissolved aliquote of all collected organs in tissue solubilizer (5:1 v/w, Soluene 350, Packard) and counted these samples after decolorization with H 2 0 2 (1:10 v/v, Merck, Darmstadt, Germany).
The data were analyzed using a one-sided ( test, p < 0.05 was considered to express significance.
RESULTS
Aliquots of all urine and bile samples of all animals were counted to determine the excretion of PhIP and its metabolites 2 h after injection (Fig. 1) . Surprisingly, the amount of excreted radioactivity, expressed as percentage of dose, in bile and urine was significantly higher in Gunn rats than in the control animals (64.4 ± 5.4% in Gunn rats vs 55.2 ± 4.7% in Wistar rats, p = 0.02). This was the result of a higher excretion in urine (19.8 ± 1.8 compared to 13.8 ± 4.4% in Gunn and Wistar, respectively, p = 0.03), while the excretion in bile was not significantly different.
We quantified the metabolites in bile and urine using integration of the radioactive peaks after separation of each sample by HPLC (see Fig. 2 for all results) .
In bile, the glucuronides of A'-OH-PhIP were reduced in Gunn rats (W 2 -glucuronide to about 63%, p = 0.009, /V 3 -glucuronide to about 30% of controls, p = 0.004). The total amount of glucuronides of 4'-OH-PhIP was not significantly different from controls, but showed a difference in the relative amounts of the three known isomers (data not shown). The excretion of PhIP itself was unchanged. 4'-OH-PhIP secretion was slightly elevated in Gunn rats (p = 0.05). The most striking difference was a more than doubled secretion of 4'-PhlP-sulfate (p = 0.0003).
The differences in urine were similar with respect to the Note. Metabolic ratio in Gunn and Wistar rats (four animals per group) in bile, urine, and in total (± SD). The amount of 4'-hydroxylated metabolites, calculated as the amounts of 4'-OH-PhIP + 4'-OH-PhIP-glucuronide + 4'-PhlP-sulfate, is divided by that of N-hydroxylated metabolites, calculated as the amounts of the N 2 -+ A^-glucuronide of A'-OH-PhIP (% of total dose each), p values are given below the respective data. The elevations of4'-OH-PhIP (130% of controls,/? = 0.005) and of 4'-PhIP-sulfate (200% of controls, p < 0.0001) in total excretion in Gunn rats, in addition to the unchanged glucuronides of 4'-OH-PhIP, showed a strong change in the metabolic ratio between 4'-hydroxylation and N-hydroxylation products. This ratio, compared to that in controls, is depicted in Table 1 .
We were not able to detect /V-OH-PhIP or its acetylated or sulfated form in blood, bile, or urine samples. The pattern of metabolites in blood reflected those from urine in both groups (data not shown).
We found that the tissue content of radioactivity 2 h after intravenous administration was reduced in liver (2.3 ± 0.47 vs 3.7 ± 0.27%) and colon (0.28 ± 0.07 vs 0.41 ± 0.08%) in Gunn rats compared to Wistar rats (Fig. 3A) , while the levels in small intestine, pancreas, kidney, heart, and lung were comparable in both animal groups. We also determined the ethanol-insoluble (covalently bound) fraction of radioactivity in both groups, which still gave a significant reduction in the liver of the Gunn rats (1.03 ± 0.16 vs 1.32 ± 0.22%, p = 0.04), while this fraction was equal between groups in all other organs (Fig. 3B) .
DISCUSSION
The present study produced two unexpected results. First, metabolism and excretion of PhIP turned out to be faster in Gunn rats than in control Wistar rats. This impression is strongly supported by the higher excretion of radioactivity in urine of the Gunn rats and by the lower amount of radioactivity in liver and colon 2 h after administration. Even though this latter difference is smaller when covalent tissue binding is determined, it remains surprising and clearly argues against the hypothesis that UGT1 deficiency increases tissue binding.
The second unexpected result is the shift in metabolism from the N-hydroxylation to the 4'-hydroxylation pathway, resulting in a preference for the detoxification pathway. In our opinion, this shift is the cause for the faster excretion of PhIP in this animal model. The ratio of 4'-hydroxylation to N-hydroxylation in PhIP metabolism normally is expected to be the result of phase I metabolism (Watkins et al, 1991b; Eisenbrand and Tang, 1993) . But how can UGT1 deficiency in phase II influence phase I metabolism?
There are two possible explanations for this change in the metabolic pathways of PhIP in the Gunn rat. First, a direct effect on phase I metabolism is possible. The activating step through CYP1A1 and CYP1A2, leading to /V-OH-PhIP, which subsequently can be metabolized further to the more genotoxic N-acetoxy-and /V-sulfoxy-PhIP (Buonarati et al, 1990) , also produces the detoxification product 4'-OH-PhIP. Rat CYP1 Al produces 4'-OH-PhIP and /V-OH-PhIP in a ratio of 3:2 and rat (heart, lungs, kidneys, pancreas, and small intestine) had radioactivity contents not significantly different between Wistar and Gunn rats. Significance levels (+p < 0.05; *p < 0.01) of Gunn rats are compared to Wistar rats. Data represent means ± SD (n = 4 in all groups).
CYP1A2 in a ratio of 1:5 (Wallin et al, 1990) , so differential regulation of these important CYP isoforms can also lead to a change in metabolic pathway ratio. But this explanation is unlikely for two reasons: The measured ratio was higher than with either enzyme; furthermore, Kapitulnik and Gonzalez (1993) could not detect any CYP1A1 mRNA in 3-month-old Gunn rats. We consider contribution of an additional CYP isoform unlikely. From the CYP isoforms other than CYP1A, only CYP1B1 has been shown to catalyze phase I metabolism of PhIP, but catalytic efficiency of this enzyme is very low and cannot account for the metabolic ratio found here (Crofts et al, 1998) . A second possible explanation is in our opinion more likely and involves alternative phase II metabolism. Sulfotransferases (SULTs) also mediate metabolism of PhIP. They catalyze the sulfation of 4'-OH-PhIP to 4'-PhIP-sulfate (Alexander et al, 1989) and the further activation of N-OH-PhIP to the genotoxic compound /V-sulfoxy-PhlP (Ozawa et al, 1994) . However, it has been speculated that SULT isoforms may also rearrange N-sulfoxy-PhlP to 4'-PhIP-sulfate, which is a clear detoxification product . In the same work it was shown that SULT1A1 activity correlated well with the excreted amount of 4'-PhIP-sulfate in humans, indicating that this latter pathway may be more common and that human SULT1A1 indeed has an important role in detoxification of PhIP. Alternative metabolism through rat SULT isoforms consequently would explain the high amount of 4'-PhIP-sulfate, the shift in metabolic ratio, and the fact that we were not able to detect yty-OH-PhlP in any of the samples. In contrast to the human situation , this alternative metabolism through SULT in the rat appears to take place predominantly in the liver. It was already suggested for metabolism of acetaminophen in humans that there might exist a compensatory mechanism between the two metabolic pathways glucuronidation and sulfation (Patel et al, 1992) . In conclusion, the observed shift in phase I metabolism pathway seen in this study is caused by molecular rearrangement in phase II and therefore may be designated as a "metabolic bypass." The corresponding effect in humans might be even bigger, since the relation between N-hydroxylation and 4'-hydroxylation is different in humans (97:1) and rats (3.3:1) , indicating that activation of PhIP through human CYP isoforms is much higher than in rats.
Another compensatory metabolic pathway, albeit minor, can be seen in UGT isoforms other than UGT1. The higher excretion of the A^-glucuronide of jV-OH-PhlP in the urine of the Gunn rat (compared to urine of the Wistar rat and in contrast to the situation in bile) is an indication that there is an additional enzyme in peripheral tissue, which has specificity for N 2 -glucuronidation of N-OH-PhlP and can compensate for lack of UGT 1 isoforms. This result is in line with immunoinhibition experiments with human microsomes (Nowell et al, 1999) , where it was demonstrated that the existence of this additional isoform, probably from the UGT2B family, for N 2 -glucuronidation is likely for the liver rather than for the colon. Interpreting these results one should bear in mind that the ratio of TVVA^-glucuronide is different in rats and humans. In rats the A^-glucuronide is the main /V-OH-PhlP-glucuronide, in humans this holds true for the A^-glucuronide (Kaderlik et al., 1994b) . This fact might be explained by different activities of UGT isoforms between liver and peripheral tissue in different species. Nevertheless, the fact that the colon, besides the main metabolic organ, the liver, contains lower tissue levels of radioactivity in the Gunn rats points to an important detoxification role of the intestine. The role of the intestine in phase II metabolism has been underestimated in the past, but is becoming clearer now for several species, including humans Mojarrabi and Mackenzie, 1998; McGurk et al, 1998) .
In summary, our results confirm that detoxification of N-OH-PhIP can also be catalyzed through alternative metabolic pathways. Enzymes of the UGT2B family probably play a role in alternative glucuronidation. In the rat this alternative glucuronidation is present most likely in peripheral tissue and therefore emphasizes the importance of extrahepatic glucuronidation. The other alternative pathway is quantitatively more important: lack of UGT 1 isoforms might facilitate and accelerate excretion of PhIP through sulfation. With compounds such as irinotecan, where glucuronidation is the only phase II metabolism pathway, UGT1 deficiency will result in accumulation and serious adverse events (Iyer et al., 1998; Wasserman et ai, 1997) . For other compounds, sulfation provides a metabolic bypass and represents an important alternative detoxification option in a state of impaired glucuronidation (Patel et al, 1992) , regardless of whether this is Crigler-Najjar disease or Gilbert's syndrome (Owens et al, 1996) . The great flexibility of these detoxification steps might also explain why there are, except for Crigler-Najjar syndrome, no severe inherited disorders known to be caused by a deficiency of UGT isoforms. Furthermore, even in the absence of the entire UGT1 family, detoxification is impaired only for some compounds. According to our results, the effects of UGT1 lack in metabolism of benzo[a]pyrene observed by Hu and Wells (1992) cannot be extrapolated to all toxic and mutagenic compounds. In contrast, we found metabolism of another important carcinogen to benefit from the absence of all UGT1 isoforms. Clearly, the cumulative consequences of lack of UGT1 on metabolism and carcinogenesis of environmental toxins still remain to be studied.
We think that the role of sulfotransferases should be further assessed under conditions lacking UGT enzymes, since there are indications that compensatory activity of sulfotransferase isoforms can lead to even more efficient detoxification and excretion of xenobiotics and carcinogens than under normal conditions.
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